Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program

Ghadeer Hasan; Elizabeth D. Ferucci; Jill P. Buyon; H. Michael Belmont; Jane E. Salmon; Anca Askanase; Joan M. Bathon; Laura Geraldino-Pardilla; Yousaf Ali; Ellen M. Ginzler; Chaim Putterman; Caroline Gordon; Charles G. Helmick; Hilary Parton; Peter M. Izmirly

doi:10.1093/rheumatology/keac703

Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program

Ghadeer Hasan, Elizabeth D. Ferucci, Jill P. Buyon, H. Michael Belmont, Jane E. Salmon, Anca Askanase, Joan M. Bathon, Laura Geraldino-Pardilla, Yousaf Ali, Ellen M. Ginzler, Chaim Putterman, Caroline Gordon, Charles G. Helmick, Hilary Parton, Peter M. Izmirly

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Objective: Epidemiological data for MCTD are limited. Leveraging data from the Manhattan Lupus Surveillance Program (MLSP), a racially/ethnically diverse population-based registry of cases with SLE and related diseases including MCTD, we provide estimates of the prevalence and incidence of MCTD. Methods: MLSP cases were identified from rheumatologists, hospitals and population databases using a variety of International Classification of Diseases, Ninth Revision codes. MCTD was defined as one of the following: fulfilment of our modified Alarcon-Segovia and Kahn criteria, which required a positive RNP antibody and the presence of synovitis, myositis and RP; a diagnosis of MCTD and no other diagnosis of another CTD; and a diagnosis of MCTD regardless of another CTD diagnosis. Results: Overall, 258 (7.7%) cases met a definition of MCTD. Using our modified Alarcon-Segovia and Kahn criteria for MCTD, the age-Adjusted prevalence was 1.28 (95% CI 0.72, 2.09) per 100 000. Using our definition of a diagnosis of MCTD and no other diagnosis of another CTD yielded an age-Adjusted prevalence and incidence of MCTD of 2.98 (95% CI 2.10, 4.11) per 100 000 and 0.39 (95% CI 0.22, 0.64) per 100 000, respectively. The age-Adjusted prevalence and incidence were highest using a diagnosis of MCTD regardless of other CTD diagnoses and were 16.22 (95% CI 14.00, 18.43) per 100 000 and 1.90 (95% CI 1.49, 2.39) per 100 000, respectively. Conclusions: The MLSP provided estimates for the prevalence and incidence of MCTD in a diverse population. The variation in estimates using different case definitions is reflective of the challenge of defining MCTD in epidemiologic studies.

Original language	English
Pages (from-to)	2845-2849
Number of pages	5
Journal	Rheumatology
Volume	62
Issue number	8
DOIs	https://doi.org/10.1093/rheumatology/keac703
State	Published - 1 Aug 2023
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

Funding

Disclosure statement: C.G. received consulting fees from the CDC, AbbVie, AstraZeneca, MGP, Sanofi and UCB and grants from UCB and Sandwell and West Birmingham Hospitals NHS Trust. P.M.I. received consulting fees from GlaxoSmithKline and Momenta/Janssen. G.H., E.D.F., J.P.B., H.M.B., J.E.S., A.A., J.M.B., L.G.-P., Y.A., E.M.G., C.P., C.G.H. and H.P. have nothing to declare. Acknowledgements This work was funded by a grant (U58/DP002827) from the CDC. This publication was supported by the CDC as part of a financial assistance award totaling $5.3 million with 100% funded by CDC/Department of Health and Human Services (HHS). Cooperative agreements between the NYC DOHMH and New York University School of Medicine provided support for this analysis.

Funders	Funder number
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
Sanofi
AbbVie
Sandwell and West Birmingham Hospitals NHS Trust
School of Public Health, University of California Berkeley

Keywords

MCTD
epidemiology
incidence
prevalence

Access to Document

10.1093/rheumatology/keac703

Cite this

Hasan, G., Ferucci, E. D., Buyon, J. P., Michael Belmont, H., Salmon, J. E., Askanase, A., Bathon, J. M., Geraldino-Pardilla, L., Ali, Y., Ginzler, E. M., Putterman, C., Gordon, C., Helmick, C. G., Parton, H., & Izmirly, P. M. (2023). Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program. Rheumatology, 62(8), 2845-2849. https://doi.org/10.1093/rheumatology/keac703

@article{13621d3183204fe1af3ded22c72b6aff,

title = "Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program",

abstract = "Objective: Epidemiological data for MCTD are limited. Leveraging data from the Manhattan Lupus Surveillance Program (MLSP), a racially/ethnically diverse population-based registry of cases with SLE and related diseases including MCTD, we provide estimates of the prevalence and incidence of MCTD. Methods: MLSP cases were identified from rheumatologists, hospitals and population databases using a variety of International Classification of Diseases, Ninth Revision codes. MCTD was defined as one of the following: fulfilment of our modified Alarcon-Segovia and Kahn criteria, which required a positive RNP antibody and the presence of synovitis, myositis and RP; a diagnosis of MCTD and no other diagnosis of another CTD; and a diagnosis of MCTD regardless of another CTD diagnosis. Results: Overall, 258 (7.7%) cases met a definition of MCTD. Using our modified Alarcon-Segovia and Kahn criteria for MCTD, the age-Adjusted prevalence was 1.28 (95% CI 0.72, 2.09) per 100 000. Using our definition of a diagnosis of MCTD and no other diagnosis of another CTD yielded an age-Adjusted prevalence and incidence of MCTD of 2.98 (95% CI 2.10, 4.11) per 100 000 and 0.39 (95% CI 0.22, 0.64) per 100 000, respectively. The age-Adjusted prevalence and incidence were highest using a diagnosis of MCTD regardless of other CTD diagnoses and were 16.22 (95% CI 14.00, 18.43) per 100 000 and 1.90 (95% CI 1.49, 2.39) per 100 000, respectively. Conclusions: The MLSP provided estimates for the prevalence and incidence of MCTD in a diverse population. The variation in estimates using different case definitions is reflective of the challenge of defining MCTD in epidemiologic studies.",

keywords = "MCTD, epidemiology, incidence, prevalence",

author = "Ghadeer Hasan and Ferucci, {Elizabeth D.} and Buyon, {Jill P.} and {Michael Belmont}, H. and Salmon, {Jane E.} and Anca Askanase and Bathon, {Joan M.} and Laura Geraldino-Pardilla and Yousaf Ali and Ginzler, {Ellen M.} and Chaim Putterman and Caroline Gordon and Helmick, {Charles G.} and Hilary Parton and Izmirly, {Peter M.}",

year = "2023",

month = aug,

day = "1",

doi = "10.1093/rheumatology/keac703",

language = "אנגלית",

volume = "62",

pages = "2845--2849",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "8",

}

Hasan, G, Ferucci, ED, Buyon, JP, Michael Belmont, H, Salmon, JE, Askanase, A, Bathon, JM, Geraldino-Pardilla, L, Ali, Y, Ginzler, EM, Putterman, C, Gordon, C, Helmick, CG, Parton, H & Izmirly, PM 2023, 'Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program', Rheumatology, vol. 62, no. 8, pp. 2845-2849. https://doi.org/10.1093/rheumatology/keac703

TY - JOUR

T1 - Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program

AU - Hasan, Ghadeer

AU - Ferucci, Elizabeth D.

AU - Buyon, Jill P.

AU - Michael Belmont, H.

AU - Salmon, Jane E.

AU - Askanase, Anca

AU - Bathon, Joan M.

AU - Geraldino-Pardilla, Laura

AU - Ali, Yousaf

AU - Ginzler, Ellen M.

AU - Putterman, Chaim

AU - Gordon, Caroline

AU - Helmick, Charles G.

AU - Parton, Hilary

AU - Izmirly, Peter M.

PY - 2023/8/1

Y1 - 2023/8/1

N2 - Objective: Epidemiological data for MCTD are limited. Leveraging data from the Manhattan Lupus Surveillance Program (MLSP), a racially/ethnically diverse population-based registry of cases with SLE and related diseases including MCTD, we provide estimates of the prevalence and incidence of MCTD. Methods: MLSP cases were identified from rheumatologists, hospitals and population databases using a variety of International Classification of Diseases, Ninth Revision codes. MCTD was defined as one of the following: fulfilment of our modified Alarcon-Segovia and Kahn criteria, which required a positive RNP antibody and the presence of synovitis, myositis and RP; a diagnosis of MCTD and no other diagnosis of another CTD; and a diagnosis of MCTD regardless of another CTD diagnosis. Results: Overall, 258 (7.7%) cases met a definition of MCTD. Using our modified Alarcon-Segovia and Kahn criteria for MCTD, the age-Adjusted prevalence was 1.28 (95% CI 0.72, 2.09) per 100 000. Using our definition of a diagnosis of MCTD and no other diagnosis of another CTD yielded an age-Adjusted prevalence and incidence of MCTD of 2.98 (95% CI 2.10, 4.11) per 100 000 and 0.39 (95% CI 0.22, 0.64) per 100 000, respectively. The age-Adjusted prevalence and incidence were highest using a diagnosis of MCTD regardless of other CTD diagnoses and were 16.22 (95% CI 14.00, 18.43) per 100 000 and 1.90 (95% CI 1.49, 2.39) per 100 000, respectively. Conclusions: The MLSP provided estimates for the prevalence and incidence of MCTD in a diverse population. The variation in estimates using different case definitions is reflective of the challenge of defining MCTD in epidemiologic studies.

AB - Objective: Epidemiological data for MCTD are limited. Leveraging data from the Manhattan Lupus Surveillance Program (MLSP), a racially/ethnically diverse population-based registry of cases with SLE and related diseases including MCTD, we provide estimates of the prevalence and incidence of MCTD. Methods: MLSP cases were identified from rheumatologists, hospitals and population databases using a variety of International Classification of Diseases, Ninth Revision codes. MCTD was defined as one of the following: fulfilment of our modified Alarcon-Segovia and Kahn criteria, which required a positive RNP antibody and the presence of synovitis, myositis and RP; a diagnosis of MCTD and no other diagnosis of another CTD; and a diagnosis of MCTD regardless of another CTD diagnosis. Results: Overall, 258 (7.7%) cases met a definition of MCTD. Using our modified Alarcon-Segovia and Kahn criteria for MCTD, the age-Adjusted prevalence was 1.28 (95% CI 0.72, 2.09) per 100 000. Using our definition of a diagnosis of MCTD and no other diagnosis of another CTD yielded an age-Adjusted prevalence and incidence of MCTD of 2.98 (95% CI 2.10, 4.11) per 100 000 and 0.39 (95% CI 0.22, 0.64) per 100 000, respectively. The age-Adjusted prevalence and incidence were highest using a diagnosis of MCTD regardless of other CTD diagnoses and were 16.22 (95% CI 14.00, 18.43) per 100 000 and 1.90 (95% CI 1.49, 2.39) per 100 000, respectively. Conclusions: The MLSP provided estimates for the prevalence and incidence of MCTD in a diverse population. The variation in estimates using different case definitions is reflective of the challenge of defining MCTD in epidemiologic studies.

KW - MCTD

KW - epidemiology

KW - incidence

KW - prevalence

UR - http://www.scopus.com/inward/record.url?scp=85166396822&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keac703

DO - 10.1093/rheumatology/keac703

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36538873

AN - SCOPUS:85166396822

SN - 1462-0324

VL - 62

SP - 2845

EP - 2849

JO - Rheumatology

JF - Rheumatology

IS - 8

ER -

Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this